Equities Analysts Set Expectations for IDYA FY2025 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of IDEAYA Biosciences in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($2.62) for the year, down from their prior estimate of ($2.35). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the firm posted ($0.53) earnings per share.

IDYA has been the subject of a number of other research reports. Stephens reiterated an “overweight” rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.58.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA opened at $18.35 on Monday. The stock has a 50-day simple moving average of $17.72 and a two-hundred day simple moving average of $22.51. The firm has a market capitalization of $1.61 billion, a P/E ratio of -5.56 and a beta of 0.26. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $44.42.

Institutional Investors Weigh In On IDEAYA Biosciences

Several institutional investors have recently bought and sold shares of IDYA. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the 4th quarter worth about $35,000. CWM LLC boosted its holdings in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after buying an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after buying an additional 1,546 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in IDEAYA Biosciences in the 4th quarter worth about $47,000. Finally, Signaturefd LLC boosted its holdings in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after buying an additional 2,271 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.